Supplementary Figure 1: Summary of clinical manifestations of patients with Majeed syndrome as described in literature. New features seen in the Indian cohort of patients are shown in bold font.


Supplementary Table 1: Radiological features and treatment of our patient cohort with Majeed syndrome:

| Patient number | 1 | 2 | 3 | 4 | 5 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Radiological findings: |  |  |  |  |  |
| Skeletal survey | Subtle, smooth periosteal reaction along the left proximal tibial metadiaphysis | Generalized reduced bone density, ankylosis b/l elbows, osteophytes left elbow, flexion deformity right elbow. Subchondral sclerosis along the proximal articular surface of ulna | Not done | Not done | Not done |
| Bone scan | Mild diffuse early and late-stage uptake in the entire left lower extremity with more focal uptake along the proximal tibia corresponding to the radiographic abnormality and mild areas of increased uptake in the tenth and eleventh vertebral | Normal | Increased uptake on early and late phase images around the right wrist, knee and ankle | Increased uptake in proximal and distal epiphysis left tibia with possible extension in the shaft on both phases | Increased blood flow around right ankle and delayed increased uptake along the distal right femur and left tibia <br> A follow up bone scan with SPECT after seven years increased early and late phase uptake around the right wrist and ankle |
| MRI | "Marrow and periosteal edema along the left distal | Not done | Right proximal humeral, radial head, distal radial | MRI left lower extremity: small left hip joint effusion, | Moderate left talonavicular effusion with mild |



|  |  |  |  | forearm with mild edema in the medial end of both clavicles |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Treatment: |  |  |  |  |  |
| Treatment | Pamidronate, methotrexate, p.r.n naproxen | Pamidronate, p.r.n diclofenac | Oral prednisolone, methotrexate, azathioprine, sulfasalazine, Pamidronate | Pamidronate, p. r. n naproxen | Oral prednisolone, methotrexate, azathioprine, sulfasalazine, etanercept, adalimumab, pamidronate |

* = Two years into treatment; ${ }^{\#}=$ One year into treatment

Abbreviations: $\mathrm{b} / \mathrm{l}=$ Bilateral; $\mathrm{y}=$ years; $\mathrm{m}=$ months

Supplementary Table 2: Novel LPIN2 mutations identified in this cohort of patients and support for their pathogenicity based on in silico predictions and ACMG classification

| Patient | Genomic coordinates | Codon change/ Amino acid substitution | gnomAD <br> MAF | Consequence | SIFT | Mutation Taster | PolyPhen | CADD | SpliceAI | ACMG <br> classification |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | $\begin{gathered} \text { Chr18: } \\ \text { 2922166G>A } \end{gathered}$ | $\begin{gathered} \mathrm{c} .2206 \mathrm{C}>\mathrm{T} \\ \text { p.R736C } \end{gathered}$ | 0.000003984 | Missense | D | D | PD | 32 | - | $\begin{aligned} & \text { VUS (PM1, } \\ & \text { PM2, PP3) } \end{aligned}$ |
| 2 | Chr18: $\begin{aligned} & 2924439- \\ & 2924441 \end{aligned}$ | c. 2041delT; <br> p.W681fs | 0 | Frameshift | - | - | - | - | - | Pathogenic (PVS1, PM2, PP3) |
| 3 | $\begin{gathered} \text { Chr18: } \\ 2923768- \\ 2923769 \mathrm{del} \end{gathered}$ | $\begin{aligned} & \text { c. } 2174+4- \\ & 2174+5 \mathrm{del} \end{aligned}$ | 0 | 5' splice site intronic variant affecting 4 nucleotides downstream donor splice site of exon 16 | - | - | - | - | 0.97 | $\begin{aligned} & \text { VUS (PM2, } \\ & \text { PP3) } \end{aligned}$ |
| 4 | Chr18: $2924522 \mathrm{C}>\mathrm{T}$ | $\begin{gathered} \text { c. } 1961 \mathrm{G}>\mathrm{A} ; \\ \text { p.G654D } \end{gathered}$ | 0 | Missense | D | D | PD | 29.9 | - | $\begin{aligned} & \text { VUS (PM1, } \\ & \text { PM2, PP3) } \end{aligned}$ |
| 5 | $\begin{gathered} \text { Chr18: } \\ 2928584 \mathrm{C}>\mathrm{G} \end{gathered}$ | c. $1620+5 \mathrm{G}>\mathrm{C}$ | 0 | 5'splice site intronic variant affecting 5 nucleotides downstream of donor splice site of exon 11 | - | D | - | 22.5 | 0.7 | $\begin{aligned} & \text { VUS (PM2, } \\ & \text { BP4) } \end{aligned}$ |

NM014646.2, All five variants are conserved across all species.
ACMG classification criterion: Pathogenic moderate 1 (PM1) = Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation; Pathogenic moderate 2 (PM2) = Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or ExAC; Pathogenic supporting 3 (PP3) = Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc); Pathogenic Very strong (PVS1) = Null variant (nonsense, frameshift, canonical $+/-1$ or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease; Benign supporting 4 (BP4) = Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)

Abbreviations: $\mathrm{D}=$ Deleterious; $\mathrm{PD}=$ Probable Damaging; VUS = Variant of uncertain significance; $\mathrm{MAF}=$ Minor allele frequency; $\mathrm{ACMG}=$ American College of Medical Genetics and Genomics

Supplementary Table 3: Salient features of twenty-five molecularly confirmed patients with Majeed syndrome reported in literature:

\begin{tabular}{|c|c|c|c|c|c|}
\hline \begin{tabular}{l}
Authors/ \\
number (n)
\end{tabular} \& Ancestry \& Consanguinity \& \begin{tabular}{l}
Gender/ \\
Age - onset/diagnosis
\end{tabular} \& Features \& Pathogenic variant \\
\hline \multirow[t]{3}{*}{\[
n=6
\]} \& \begin{tabular}{l}
Arabic \\
Sibship 1
\end{tabular} \& + \& F/9m/NA

M/NA/NA \& \begin{tabular}{l}
Failure to thrive \\
Recurrent fever \\
CRMO \\
Microcytic anemia \\
${ }^{\text {a }}$ Skin lesions \\
Hepatosplenomegaly

 \& 

Homozygous for

$$
\text { c. } 2201 \mathrm{C}>\mathrm{T} \text {; }
$$ \\

p.Ser734Leu
\end{tabular} \\

\hline \& | Arabic |
| :--- |
| Sibship 2 | \& + \& M/6m/NA

M/10m/NA \& \begin{tabular}{l}
Failure to thrive \\
Recurrent fever \\
CRMO \\
Microcytic anemia \\
Sweet syndrome \\
Hepatosplenomegaly

 \& 

Homozygous for

$$
\text { c. } 2201 \mathrm{C}>\mathrm{T}
$$ \\

p.Ser734Leu
\end{tabular} \\

\hline \& \& + \& * F/3w/NA \& Failure to thrive \& Homozygous for \\
\hline
\end{tabular}

|  | Arabic <br> Sibship 3 |  | \# $\mathrm{M} / 2 \mathrm{~m} / \mathrm{NA}$ | ${ }^{\mathrm{b}}$ Recurrent fever <br> ${ }^{\text {c }}$ CRMO <br> ${ }^{\mathrm{d}}$ Microcytic anemia <br> *Splenomegaly <br> \# Irritability <br> \# Delayed Puberty <br> \# Pustulosis <br> \# Contractures: UL/LL <br> \# Maxillary bone hyperplasia <br> \# Prominent forehead <br> \# Splenectomy | $\begin{aligned} & \text { c.540_541del; } \\ & \text { p.Cys181* } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Al - Mosawi et <br> al. (18) $\mathbf{n}=\mathbf{1}$ | Arabic | + | F/Neonatal/ UC | Recurrent fever <br> CRMO <br> Microcytic anemia <br> Reticulocytosis <br> Mild neutropenia <br> Cholestatic jaundice | Homozygous for $\text { c. } 2327+1 \mathrm{G}>\mathrm{C}$ <br> p.Arg776Serfs*66 |


|  |  |  |  | Hepatosplenomegaly |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Herlin et al. | Turkish | + | M/6m/29m | CRMO | Homozygous for |
| (14) | Sibship 4 |  |  | Microcytic anemia | c.1312_1313del; |
| $\mathrm{n}=2$ |  |  |  | Elevated IL-1 $\beta$, IL-6, IL-8 | p.Ser439Trpfs*15 |
|  |  |  |  | TNF- $\alpha$ |  |
|  |  |  | ${ }^{\$} \mathrm{M} / 3 \mathrm{~m} / 13 \mathrm{~m}$ |  |  |
|  |  |  |  | ${ }^{\$}$ Recurrent fever |  |
| Rao et al. (19)n $=2$ | Indian |  | M/2y/15y | Failure to thrive | Homozygous for |
|  | Cousins |  |  | Delayed puberty | c.2241_2243delinsGG;p.Tyr747* |
|  |  |  |  | CRMO |  |
|  |  |  |  | Microcytic anemia | p.Tyr747* |
|  |  |  |  | Mild leucopenia |  |
|  |  |  |  | Hepatosplenomegaly |  |
|  |  |  | M/8y/13y | Failure to thrive |  |
|  |  |  |  | CRMO |  |
|  |  |  |  | Mild Microcytic anemia |  |
| Fernandes et | NA | NA | M/6y/12y | CRMO | Homozygous for |
| al. (20) |  |  |  | Alpha - thalassemia minor | c. $2327+1 \mathrm{G}>\mathrm{C}$; |
|  |  |  |  |  | p.Arg776Serfs*66 |



|  |  |  | F (sib)/NA/NA | Mild anemia <br> Limb pain |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Father/NA/NA | Non-specific knee pain |  |
| Liu et al. (13) $\mathrm{n}=1$ | Chinese | No | M/6m/UC | Recurrent fever <br> Microcytic anemia <br> Severe neutropenia | Compound heterozygous <br> for $\begin{aligned} & \text { c. } 2327+1 \mathrm{G}>\mathrm{C} \\ & \text { p. } \operatorname{Arg} 776 \text { Serfs } * 66 \end{aligned}$ <br> and <br> c.1691_1694del; <br> p.Arg564Lysfs*3 |
| Bhuyan et al. <br> (9) $\mathrm{n}=1$ | American |  | F/12m/4y | Dyserythropoietic anemia <br> Bone pains | Compound heterozygous $\text { c. } 1550 \mathrm{G}>\mathrm{A} ;$ <br> p.Arg517His and <br> 17.8 kb deletion of exons 7 to 18 |

In addition to these, twenty-five patients with pathogenic or likely pathogenic variants in LPIN2, six other patients (12) were reported to have a homozygous mutation in $L P I N 2$, but these variants were not described. ${ }^{\mathrm{a}}=$ Skin lesion resembling Sweet syndrome; ${ }^{\mathrm{b}}=$ high grade; $\mathrm{c}=$ extensive involvement; ${ }^{\mathrm{d}}=$ transfusion dependent; ${ }^{\mathrm{e}}=$ nocturnal pain

Abbreviations: M=Male; F =Female; $3^{0}=3^{\text {rd }}$ degree; NA= Not Available; $w=$ weeks; $m=$ months; $\mathrm{y}=$ years; CRMO $=$ Chronic Recurrent Multifocal Osteomyelitis; UC = Unclear; UL = Upper Limb; LL = Lower Limb.

